Cited by 327PARP inhibition in cancer therapyBRCA gene mutations in cancerCancer Genomics and Diagnostics

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers

Open access

Watkins, Johnathan A, Irshad, Sheeba, Grigoriadis, Anita, Tutt, Andrew NJ·2014·Breast Cancer Research

Open this paper in CoChat — free account

Abstract

Poly (ADP-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapies have been found to be particularly effective in tumors that harbor deleterious germline or somatic mutations in the BRCA1 or BRCA2 genes, the products of which contribute to the conservative homologous recombination repair of DNA double-strand breaks. Nonetheless, several setbacks in clinical trial settings have highlighted some of the issues surrounding the investigation of PARP inhibitors, especially the identification of patients who stand to benefit from such drugs. One potential approach to finding this patient subpopulation is to examine the tumor DNA for evidence of a homologous recombination defect. However, although the genomes of many breast and ovarian cancers are replete with aberrations, the presence of numerous factors able to shape the genomic landscape means that only some of the observed DNA abnormalities are the outcome of a cancer cell's inability to faithfully repair DNA double-strand breaks. Consequently, recently developed methods for comprehensively capturing the diverse ways in which homologous recombination deficiencies may arise beyond BRCA1/2 mutation have used DNA microarray and sequencing data to account for potentially confounding features in the genome. Scores capturing telomeric allelic imbalance, loss of heterozygosity (LOH) and large scale transition score, as well as the total number of coding mutations are measures that summarize the total burden of certain forms of genomic abnormality. By contrast, other studies have comprehensively catalogued different types of mutational pattern and their relative contributions to a given tumor sample. Although at least one study to explore the use of the LOH scar in a prospective clinical trial of a PARP inhibitor in ovarian cancer is under way, limitations that result in a relatively low positive predictive value for these biomarkers remain. Tumors whose genome has undergone one or more events that restore high-fidelity homologous recombination are likely to be misclassified as double-strand break repair-deficient and thereby sensitive to PARP inhibitors and DNA damaging chemotherapies as a result of prior repair deficiency and its genomic scarring. Therefore, we propose that integration of a genomic scar-based biomarker with a marker of resistance in a high genomic scarring burden context may improve the performance of any companion diagnostic for PARP inhibitors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1186/bcr3670

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Self-citation
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Self-citation
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Self-citation
Clonal evolution in cancer
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Self-citation
Mutational Processes Molding the Genomes of 21 Breast Cancers
Nik-Zainal, S., Alexandrov, L. B., Wedge, D. C., Van Loo, P., Greenman, C. D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.024 · Cited by 1,909
Self-citation
Cancer as an evolutionary and ecological process
Merlo, L. M. F., Pepper, J. W., Reid, B. J., & Maley, C. C. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2013 · Cited by 1,743

Flagged first, then by citations

Show all 58 references

Research works printed but not linked: 1

de Bono JS, Mina LA, Gonzalez M, Curtin NJ, Wang E, Henshaw JW, Chadha M, Sachdev JC, Matei D, Jameson GS, Ong M, Basu B, Wainberg ZA, Byers LA, Chugh R, Dorr A, Kaye SB, Ramanthan RK: First-in human trial of novel oral PARP inhibitor BMN673 in patients with solid tumors. J Clin Oncol. 2013, 31: abstract 2580

Sorted by citations

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C. A., Oaknin, A., Dean, A. P., Colombo, N., Weberpals, J. I., Clamp, A. R., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,699
BRCAness revisited
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Davies, H., Glodzik, D., Morganella, S., Yates, L. R., Staaf, J., Zou, X., Ramakrishna, M., Martin, S., Boyault, S., Sieuwerts, A. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4292 · Cited by 1,086
Self-citation
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Knijnenburg, T., Wang, L., Zimmermann, M. T., Chambwe, N., Gao, G. F., Cherniack, A. D., Fan, H., Shen, H., Way, G. P., Greene, C. S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.076 · Cited by 1,145
Pathogenesis of Triple-Negative Breast Cancer
Derakhshan, F., & Reis-Filho, J. S. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042420-093238 · Cited by 714
Unravelling the biology of SCLC: implications for therapy
Sabari, J. K., Lok, B. H., Laird, J. H., Poirier, J. T., & Rudin, C. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.71 · Cited by 493
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
Cruz, C., Castroviejo‐Bermejo, M., Gutiérrez‐Enríquez, S., Llop‐Guevara, A., Ibrahim, Y. H., Gris‐Oliver, A., Bonache, S., Morancho, B., Bruna, A., Rueda, O. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy099 · Cited by 454
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance
Secrier, M., Li, X., de Silva, N., Eldridge, M., Contino, G., Bornschein, J., MacRae, S., Grehan, N., O’Donovan, M., Miremadi, A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3659 · Cited by 402
Triple-negative breast cancer: treatment challenges and solutions
Jérusalem, G., Collignon, J., Schroeder, H., & Lousberg, L. (2016) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s69488 · Cited by 409
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 360
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Lok, B. H., Gardner, E. E., Schneeberger, V. E., Ni, A., Desmeules, P., Rekhtman, N., de Stanchina, E., Teicher, B. A., Riaz, N., Powell, S. N., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1040 · Cited by 350
Precision medicine for metastatic breast cancer—limitations and solutions
Arnedos, M., Vicier, C., Loi, S., Lefèbvre, C., Michiels, S., Bonnefoi, H. R., & André, F. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.123 · Cited by 322
Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs
Marquard, A. M., Eklund, A. C., Joshi, T., Krzystanek, M., Favero, F., Wang, Z. C., Richardson, A. L., Silver, D. P., Szállási, Z., & Birkbak, N. J. (2015) · Biomarker Research · doi:10.1186/s40364-015-0033-4 · Cited by 308
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
Kalimutho, M., Parsons, K., Mittal, D., López, J. A., Srihari, S., & Khanna, K. K. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.08.009 · Cited by 298
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer
Moschetta, M., George, A. J., Kaye, S. B., & Banerjee, S. N. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw142 · Cited by 299
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
Chakravarty, D., Johnson, A., Sklar, J., Lindeman, N. I., Moore, K. N., Ganesan, S., Lovly, C. M., Perlmutter, J., Gray, S. W., Hwang, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02767 · Cited by 301
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Castroviejo‐Bermejo, M., Cruz, C., Llop‐Guevara, A., Gutiérrez‐Enríquez, S., Ducy, M., Ibrahim, Y. H., Gris‐Oliver, A., Pellegrino, B., Bruna, A., Guzmán, M., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809172 · Cited by 282
The current state of molecular testing in the treatment of patients with solid tumors, 2019
El‐Deiry, W. S., Goldberg, R. M., Lenz, H., Shields, A. F., Gibney, G. T., Tan, A. R., Brown, J., Eisenberg, B., Heath, E. I., Phuphanich, S., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21560 · Cited by 264
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
Chopra, N., Tovey, H., Pearson, A., Cutts, R., Toms, C., Proszek, P., Hubank, M. J. F., Dowsett, M., Dodson, A. R., Daley, F. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16142-7 · Cited by 267
Self-citation
Pharmacogenomics: Driving Personalized Medicine
Sadée, W., Wang, D., Hartmann, K., & Toland, A. E. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000810 · Cited by 264
Homologous recombination deficiency and ovarian cancer
Ledermann, J. A., Drew, Y., & Kristeleit, R. S. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.005 · Cited by 258
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Hodgson, D., Dougherty, B. A., Lai, Z., Fielding, A., Grinsted, L. M., Spencer, S., O’Connor, M. J., Ho, T. W., Robertson, J. D., Lanchbury, J. S. S., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0274-8 · Cited by 233
PARP inhibitors: Clinical utility and possibilities of overcoming resistance
Bitler, B. G., Watson, Z. L., Brubaker, L. W., & Behbakht, K. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.10.003 · Cited by 224
Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications
Asleh, K., Riaz, N., & Nielsen, T. O. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02476-1 · Cited by 235
Heterogeneity and treatment landscape of ovarian carcinoma
Veneziani, A. C., González-Ochoa, E., Alqaisi, H. A., Madariaga, A., Bhat, G. R., Rouzbahman, M., Sneha, S., & Oza, A. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00819-1 · Cited by 228
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Swisher, E. M., Kwan, T. T., Oza, A. M., Tinker, A. V., Ray-Coquard, I. L., Oaknin, A., Coleman, R. L., Aghajanian, C. A., Konecny, G. E., O’Malley, D. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22582-6 · Cited by 209
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
Gourley, C., Balmañà, J., Ledermann, J. A., Serra, V., Dent, R. A., Loibl, S., Pujade-Lauraine, É., & Boulton, S. J. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02050 · Cited by 195
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Shroff, R. T., Hendifar, A. E., McWilliams, R. R., Geva, R., Epelbaum, R., Rolfe, L., Goble, S. M., Lin, K., Biankin, A. V., Giordano, H., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00316 · Cited by 183
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Jurkovičová, D., Neophytou, C. M., Gašparović, A. Č., & Gonçalves, A. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314672 · Cited by 175
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
Vergote, I. B., González-Martı́n, A., Ray-Coquard, I., Harter, P., Colombo, N., Pujol, P., Lorusso, D., Mirza, M. R., Brasiūnienė, B., Madry, R., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.11.013 · Cited by 161
PARP Inhibitors in Ovarian Cancer
Mittica, G., Ghisoni, E., Giannone, G., Genta, S., Aglietta, M., Sapino, A., & Valabrega, G. (2018) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892813666180305165256 · Cited by 158
PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
Keung, M., Wu, Y., & Vadgama, J. V. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040435 · Cited by 158
Biomarkers of Response and Resistance to DNA Repair Targeted Therapies
Stover, E. H., Konstantinopoulos, P. A., Matulonis, U. A., & Swisher, E. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0247 · Cited by 149
Molecular Classification of Triple-Negative Breast Cancer
Ahn, S. G., Kim, S. J., Kim, C., & Jeong, J. (2016) · Journal of Breast Cancer · doi:10.4048/jbc.2016.19.3.223 · Cited by 146
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
Boussios, S., Abson, C., Moschetta, M., Rassy, E., Karathanasi, A., Bhat, T., Ghumman, F. I. A., Sheriff, M., & Pavlidis, N. A. (2020) · Drugs in R&D · doi:10.1007/s40268-020-00301-8 · Cited by 142
The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
Ngoi, N. Y. L., & Tan, D. S. P. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100144 · Cited by 138
Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies
Minchom, A. R., Aversa, C., & Lopez, J. S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918786658 · Cited by 138
Mutational Signatures in Breast Cancer: The Problem at the DNA Level
Nik‐Zainal, S., & Morganella, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2810 · Cited by 139
An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer
Cosgrove, C. M., Tritchler, D., Cohn, D. E., Mutch, D. G., Rush, C. M., Lankes, H. A., Creasman, W. T., Miller, D. S., Ramirez, N. C., Geller, M. A., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.10.037 · Cited by 132
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
Gruber, J. J., Afghahi, A., Timms, K. M., DeWees, A., Gross, W., Aushev, V. N., Wu, H.-T., Balcioglu, M., Sethi, H., Scott, D., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00439-1 · Cited by 135
Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
Cocco, S., Piezzo, M., Calabrese, A., Cianniello, D., Caputo, R., Lauro, V. D., Fusco, G., Gioia, G. D., Licenziato, M., & Laurentiis, M. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134579 · Cited by 127
Portrait of a cancer: mutational signature analyses for cancer diagnostics
Van Hoeck, A., Tjoonk, N. H., van Boxtel, R., & Cuppen, E. (2019) · BMC Cancer · doi:10.1186/s12885-019-5677-2 · Cited by 107
Advances and perspectives of PARP inhibitors
Yi, M., Dong, B., Qin, S., Chu, Q., Wu, K., & Luo, S. (2019) · Experimental Hematology & Oncology · doi:10.1186/s40164-019-0154-9 · Cited by 117
Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors
Mekonnen, N., Yang, H., & Shin, Y. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.880643 · Cited by 117
Clinical assays for assessment of homologous recombination DNA repair deficiency
Stover, E. H., Fuh, K. C., Konstantinopoulos, P. A., Matulonis, U. A., & Liu, J. F. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.09.029 · Cited by 111
Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets
Paul, M. R., Pan, T.-C., Pant, D. K., Shih, N. N. C., Chen, Y., Harvey, K. L., Solomon, A. C., Lieberman, D. B., Morrissette, J. J. D., Soucier-Ernst, D., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129941 · Cited by 108
Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers
Nones, K., Johnson, J., Newell, F., Patch, A. M., Thorne, H., Kazakoff, S. H., de Luca, X. M., Parsons, M. T., Ferguson, K., Reid, L. E., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz132 · Cited by 93
“Germline testing is also impacting therapy, since carriers of germline pathogenic BRCA1/2 variants derive enhanced benefit from platinum-based chemotherapy or poly(ADP-ribose) polymerase inhibitors (PARPi) [2–7].”
Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial
Llop‐Guevara, A., Loibl, S., Villacampa, G. J., Vladimirova, V. A., Schneeweiß, A., Karn, T., Zahm, D.-M., Herencia-Ropero, A., Jank, P., van Mackelenbergh, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.003 · Cited by 101
Homologous recombination proficiency in ovarian and breast cancer patients
Creeden, J. F., Nanavaty, N. S., Einloth, K. R., Gillman, C. E., Stanbery, L., Hamouda, D., Dworkin, L. D., & Nemunaitis, J. J. (2021) · BMC Cancer · doi:10.1186/s12885-021-08863-9 · Cited by 96
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer
Chowdhury, S., Kennedy, J. J., Ivey, R. G., Murillo, O. D., Hosseini, N., Song, X., Petralia, F., Calinawan, A. P., Savage, S. R., Berry, A. B., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.004 · Cited by 95
Homologous Recombination Deficiency in Breast Cancer: A Clinical Review
den Brok, W. D., Schrader, K. A., Sun, S. B., Tinker, A. V., Stutheit-Zhao, E. Y., Aparicio, S. A. J. R., & Gelmon, K. A. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00031 · Cited by 86
Patterns of Genomic Instability in Breast Cancer
Kalimutho, M., Nones, K., Srihari, S., Duijf, P. H. G., Waddell, N., & Khanna, K. K. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.01.005 · Cited by 87
PARP Inhibitors Resistance: Mechanisms and Perspectives
Giudice, E., Gentile, M., Salutari, V., Ricci, C., Musacchio, L., Carbone, M. V., Ghizzoni, V., Camarda, F., Tronconi, F., Nero, C., et al. (2022) · Cancers · doi:10.3390/cancers14061420 · Cited by 95
The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer
Mauri, G., Arena, S., Siena, S., Bardelli, A., & Bianchi, A. S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.027 · Cited by 87
Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
Dilmaç, S., & Özpolat, B. (2023) · Cancers · doi:10.3390/cancers15143642 · Cited by 96
PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity
Gupta, S. K., Smith, E. J., Mladek, A. C., Tian, S., Decker, P. A., Kizilbash, S. H., Kitange, G. J., & Sarkaria, J. N. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00670 · Cited by 82
Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas
Manié, É., Popova, T. G., Battistella, A., Tarabeux, J., Caux‐Moncoutier, V., Golmard, L., Smith, N. K., Mueller, C. R., Mariani, O., Sigal‐Zafrani, B., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29829 · Cited by 80
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker
Mayer, E. L., Abramson, V. G., Jankowitz, R. C., Falkson, C. I., Marcom, P. K., Traina, T., Carey, L., Rimawi, M. F., Specht, J. M., Miller, K. D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2064 · Cited by 78
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial
Wolf, D. M., Yau, C. S. F., Sanil, A. P., Glas, A. M., Petricoin, E. F., Wulfkuhle, J. D., Severson, T., Linn, S. C., Swigart, L. B., Hirst, G. L., et al. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0025-7 · Cited by 76
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review
Pellegrino, B., Musolino, A., Llop‐Guevara, A., Serra, V., Silva, P. D., Hlavata, Z., Sangiolo, D., Willard-Gallo, K. E., & Solinas, C. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.10.010 · Cited by 77
Wise Management of Ovarian Cancer: On the Cutting Edge
Boussios, S., Mikropoulos, C., Samartzis, E. P., Karihtala, P., Moschetta, M., Sheriff, M., Karathanasi, A., Sadauskaite, A., Rassy, E., & Pavlidis, N. A. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10020041 · Cited by 74
Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?
Pellegrino, B., Mateo, J., Serra, V., & Balmañà, J. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000480 · Cited by 72
Single-Cell Analysis of Circulating Tumor Cells: Why Heterogeneity Matters
Lim, S. B., Lim, C. T., & Lim, W. (2019) · Cancers · doi:10.3390/cancers11101595 · Cited by 73
Biomarkers for Homologous Recombination Deficiency in Cancer
Wagener‐Ryczek, S., Merkelbach‐Bruse, S., & Siemanowski, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11070612 · Cited by 71
Successes and Challenges of PARP Inhibitors in Cancer Therapy
Ricks, T. K., Chiu, H.-J., Ison, G., Kim, G., McKee, A. E., Kluetz, P. G., & Pazdur, R. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00222 · Cited by 70
Bi‐allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer
Mutter, R. W., Riaz, N., Ng, C. K. Y., Delsite, R., Piscuoglio, S., Edelweiss, M., Martelotto, L. G., Sakr, R. A., King, T. A., Giri, D. D., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4890 · Cited by 68
Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine
Yee, C., Dickson, K.-A., Muntasir, M. N., Ma, Y., & Marsh, D. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.836984 · Cited by 66
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Morgan, R. D., Clamp, A. R., Evans, D. G., Edmondson, R. J., & Jayson, G. C. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3532-9 · Cited by 66
Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer
Vanderstichele, A., Busschaert, P., Olbrecht, S., Lambrechts, D., & Vergote, I. B. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.029 · Cited by 62
Novel targets in the treatment of advanced gastric cancer: a perspective review
Fontana, E., & Smyth, E. C. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015616935 · Cited by 62
Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer
Chun, K., Park, J. H., & Fan, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_4 · Cited by 60
Histo‐genomic stratification reveals the frequent amplification/overexpression of CCNE 1 and BRD 4 genes in non‐BRCAness high grade ovarian carcinoma
Goundiam, O., Gestraud, P., Popova, T. G., Rouge, T. D. L. M., Fourchotte, V., Gentien, D., Hupé, P., Becette, V., Houdayer, C., Roman‐Roman, S., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29568 · Cited by 61
The current landscape of molecular profiling in the treatment of epithelial ovarian cancer
Haunschild, C., & Tewari, K. S. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.09.043 · Cited by 58
Cytotoxic and targeted therapy for hereditary cancers
Iyevleva, A. G., & Имянитов, Е. Н. (2016) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-016-0057-2 · Cited by 57
Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors
Paulet, L., Trécourt, A., Leary, A. F., Péron, J., Descôtes, F., Devouassoux‐Shisheboran, M., Leroy, K., You, B., & Lopez, J. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.037 · Cited by 57
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies
Steenbruggen, T. G., van Ramshorst, M. S., Kok, M., Linn, S. C., Smorenburg, C. H., & Sonke, G. S. (2017) · Drugs · doi:10.1007/s40265-017-0774-5 · Cited by 57
Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis
Greene, S. B., Dago, A. E., Leitz, L., Wang, Y., Lee, J. S. H., Werner, S. L., Gendreau, S. B., Patel, P. H., Jia, S., Zhang, L., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165089 · Cited by 56
Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization
Sajjadi, E., Venetis, K., Piciotti, R., Invernizzi, M., Guerini‐Rocco, E., Haricharan, S., & Fusco, N. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01976-y · Cited by 51
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing
Barili, V., Ambrosini, E., Bortesi, B., Minari, R., Sensi, E. D., Cannizzaro, I. R., Taiani, A., Michiara, M., Sikokis, A., Boggiani, D., et al. (2024) · Genes · doi:10.3390/genes15020219 · Cited by 56
High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1 -like Breast Cancer
Schouten, P. C., Vollebergh, M. A., Opdam, M., Jonkers, M., Lodén, M., Wesseling, J., Hauptmann, M., & Linn, S. C. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0470 · Cited by 50
High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer
Judes, G., Rifai, K. T., Daures, M., Dubois, L., Bignon, Y., Penault-Llorca, F. M., & Bernard-Gallon, D. J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.001 · Cited by 50
Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response
Picciotto, N. D., Cacheux, W., Roth, A. D., Chappuis, P. O., & Labidi‐Galy, S. I. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.02.014 · Cited by 51
PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic
Gadducci, A., & Guerrieri, M. E. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.04.006 · Cited by 51
Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine
Murata, S., Zhang, C., Finch, N., Zhang, K., Campo, L., & Breuer, E.-K. Y. (2016) · BioMed Research International · doi:10.1155/2016/2346585 · Cited by 47
Using next‐generation sequencing to redefineBRCAnessin triple‐negative breast cancer
Lin, P., Chen, M., Tsai, L., Lo, C., Yen, T., Huang, T. Y., Chen, C., Fan, S., Kuo, S., & Huang, C. (2020) · Cancer Science · doi:10.1111/cas.14313 · Cited by 46
Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer
Catalano, F., Borea, R., Puglisi, S., Boutros, A., Gandini, A., Cremante, M., Martelli, V., Sciallero, S., & Puccini, A. (2022) · Cancers · doi:10.3390/cancers14061388 · Cited by 44
Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics
Witz, A., Dardare, J., Betz, M., Michel, C., Husson, M., Gilson, P., Merlin, J., & Harlé, A. (2025) · Biomarker Research · doi:10.1186/s40364-025-00740-y · Cited by 52
Mutational signatures associated with exposure to carcinogenic microplastic compounds bisphenol A and styrene oxide
Hu, X., Biswas, A., Sharma, A., Sarkodie, H., Tran, I., Pal, I., & De, S. (2021) · NAR Cancer · doi:10.1093/narcan/zcab004 · Cited by 44
New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors
Liu, F. W., & Tewari, K. S. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0378-9 · Cited by 46
PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches
Barayan, R., Ran, X., & Lok, B. H. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.89 · Cited by 43
Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy
Jin, J., Zhang, W., Ji, W., Yang, F., & Guan, X. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1323582 · Cited by 44
Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation
Ladan, M. M., van Gent, D. C., & Jager, A. (2021) · Cancers · doi:10.3390/cancers13051004 · Cited by 45
Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy
Huang, J.-L., Chang, Y.-T., Hong, Z.-Y., & Lin, C.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063238 · Cited by 42
Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data
Chartron, E., Theillet, C. G., Guiu, S., & Jacot, W. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.10.012 · Cited by 40
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer
Swisher, E. M., Kristeleit, R. S., Oza, A. M., Tinker, A. V., Ray-Coquard, I. L., Oaknin, A., Coleman, R. L., Burris, H. A., Aghajanian, C. A., O’Malley, D. M., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.08.030 · Cited by 39
Therapeutic targeting and patient selection for cancers with homologous recombination defects
Talens, F., Jalving, M., Gietema, J. A., & van Vugt, M. A. T. M. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1322061 · Cited by 41
Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction
Chiang, Y., Lin, P., & Cheng, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.675972 · Cited by 38
The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others
Chen, Y., & Du, H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.01.094 · Cited by 37

Authors: Watkins, J. A., Irshad, S., Grigoriadis, A., & Tutt, A. N.
Affiliations: Guy's Hospital (GB)
Corresponding author: Grigoriadis, Anita
ORCID: Watkins, Johnathan A
Irshad, Sheeba
Grigoriadis, Anita
Tutt, Andrew NJ
Venue: Breast Cancer Research
Publisher: Springer Science and Business Media LLC
Published: 2014-06-03
Volume: 16
Issue: 3
Pages: 211-211
ISSN: 1465-5411 (ISSN-L)
1465-542X
DOI: 10.1186/bcr3670
PMC: PMC4053155
OpenAlex: W2100419317
Cited by: 327
References: 58
Citations by year: 2026: 14 · 2025: 14 · 2024: 21 · 2023: 31 · 2022: 54 · 2021: 42 · 2020: 25 · 2019: 25 · 2018: 23 · 2017: 27 · 2016: 35 · 2015: 15 · 2014: 1
FWCI: 2.95
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
www.springer.com/tdm (unspecified)
Locations: Breast Cancer Research (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Research Portal (King's College London) (publishedVersion, other-oa)
Funders: National Institute for Health and Care Research
King's College London
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: homologous recombination deficiency, PARP inhibitors, BRCA1, BRCA2, loss of heterozygosity, telomeric allelic imbalance, mutational signatures, drug response biomarkers, breast cancer, ovarian cancer, DNA double-strand break repair, platinum-based chemotherapy, companion diagnostics, predictive biomarkers
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Breast Neoplasms, Chromosome Aberrations, Female, Humans, Ovarian Neoplasms, Biomarkers, Tumor, BRCA1 Protein, BRCA2 Protein, DNA Breaks, Double-Stranded, Homologous Recombination, Recombinational DNA Repair

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks